Circadian owns Vegenics

By Dylan Bushell-Embling
Thursday, 14 August, 2008

Circadian Technologies [ASX: CIR] is now the sole owner of Vegenics, having completed the acquisition of the company today.

Circadian announced the planned acquisition on July 15. Prior to that point, the company held a 66 per cent stake in Vegenics.

Among the intellectual property Circadian has assumed control of are the proteins VEGF-C and VEGF-D, which if blocked may inhibit rumour growth and prevent the spread of new cancer cells.

Circadian has also acquired Vegenics' product pipeline, including drug candidates based on the VEGF-C and VEGF-D protein IPs.

Content from other channels on our network

Urinary incontinence and cardiovascular disease risk in women

Pharmacist distraction during dispensing — extent and sources

Ambulance ramping — its "very real potential human consequences"

Could this game wave goodbye to nerve pain?

Inaugural Hospital + Healthcare Excellence Awards — nominations open

Enabling OT continuous monitoring

Ghost Bat a major milestone for local defence manufacturing

Central Coast Council completes first remote sewer inspection

From smart to vulnerable: The hidden costs of the digitalisation of utilities

Copper SA partners with Aurizon for copper logistics

GNT shows how plant-based colours can liven up snacks

Getting a handle on a shrink bag for turkey

Six on the shelf: from frozen snacks to GF treats

Visibly conveying freshly roasted coffee direct to the consumer

Sobering up with the latest wine trends

Circadian owns Vegenics

Organoid platform enables closer study of bat-borne viruses

Global study finds 250 genes linked to OCD

TGA approves therapy for paediatric growth hormone deficiency

Content from other channels on our network